证券代码：605016 证券简称：百龙创园 公告编号：2023-045 山东百龙创园生物科技股份有限公司 关于泰国子公司的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、对外投资概述 山东百龙创园生物科技股份有限公司（以下简称"公司"）于 2023 年 10 月 20 日 召开了第三届董事会第六次会议，审议通过《关于投资建设泰国生产基地的议案》， 董事会同意授权经营层或授权人员全权办理公司本次设立泰国子公司、泰国生产基地 建设有关的全部事宜。 上述具体内容详见 2023 年 10 月 21 日公司披露于上海证券交易所网站 （http://www.sse.com.cn）的《关于投资建设泰国生产基地的公告》（公告编号： 2023-039）。 二、进展情况及泰国子公司基本情况 1、截至本公告披露日，公司已完成泰国子公司的国内备案登记事宜，并先后取 得了由山东省商务厅颁发的《企业境外投资证书》（境外投资证第 N3700202300299 号）、山东省发展和改革委员会颁发的《境外投资项目备案通知书》（鲁发改外资备 [ ...

证券代码：605016 证券简称：百龙创园 公告编号：2023-044 山东百龙创园生物科技股份有限公司 关于控股股东部分股权质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ●山东百龙创园生物科技股份有限公司（以下简称"公司"）控股股东窦宝 德先生持有公司股份 117,649,000 股，占公司总股本的比例为 47.34%。窦宝德 先生股份累计质押数量为 22,340,000 股，占其所持有公司股份总额的比例为 18.99%，占公司总股本的比例为 8.99%。 一、本次股份质押的基本情况 公司近日收到控股股东窦宝德先生关于其所持公司部分股份被质押的通知， 具体事项如下： | | 是否为 | | 是否为限售 | | | | | 占其所 | 占公司 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 控股股 | 本次质押股 | 股（如是， | 是否补 | 质押起 | 质押到 | 质权人 | 持股份 | ...

Financial Performance - The company's operating revenue for Q3 2023 reached ¥241,035,316.38, representing a year-on-year increase of 52.74%[2] - The net profit attributable to shareholders for the same period was ¥50,239,853.54, reflecting a growth of 27.07% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses was ¥48,472,196.25, which is an increase of 43.23% year-on-year[2] - Total operating revenue for the first three quarters of 2023 reached ¥653,792,099.94, an increase of 18.73% compared to ¥550,364,964.66 in the same period of 2022[18] - Net profit for the first three quarters of 2023 was ¥141,339,479.77, representing a 19.83% increase from ¥117,990,687.04 in the same period of 2022[19] - The basic earnings per share for Q3 2023 was ¥0.20, a decrease of 9.09% compared to the same period last year[3] - Earnings per share for the first three quarters of 2023 were ¥0.57, down from ¥0.66 in the previous year[20] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥143,909,006.92, showing a significant increase of 34.25%[6] - Cash inflow from operating activities for the first three quarters of 2023 reached ¥658,899,880.93, an increase of 10.1% compared to ¥598,015,458.69 in the same period of 2022[21] - Net cash flow from operating activities amounted to ¥143,909,006.92, up 34.3% from ¥107,197,630.33 in the previous year[21] - Cash inflow from investment activities totaled ¥564,255,893.73, compared to ¥471,942,593.46 in the same period of 2022, marking an increase of 19.5%[22] - Net cash flow from investment activities was -¥116,957,908.46, an improvement from -¥170,324,042.69 in the previous year[22] - Cash inflow from financing activities was ¥50,000,000.00, while cash outflow for financing activities was ¥32,714,725.56, resulting in a net cash flow of ¥17,285,274.44, compared to -¥10,291,051.68 in the same period of 2022[22] - The net increase in cash and cash equivalents for the period was ¥44,249,718.20, contrasting with a decrease of -¥73,406,121.44 in the previous year[22] - The ending balance of cash and cash equivalents was ¥225,148,141.47, compared to ¥217,635,303.25 at the end of the same period in 2022[22] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,654,564,488.78, marking a 12.41% increase from the end of the previous year[3] - As of September 30, 2023, the company's total assets reached RMB 1,654,564,488.78, an increase from RMB 1,471,953,421.03 at the end of 2022, reflecting a growth of approximately 12.4%[13] - The company's cash and cash equivalents amounted to RMB 283,236,705.47, up from RMB 191,691,246.67 in December 2022, indicating a growth of about 47.7%[13] - Accounts receivable increased to RMB 194,773,586.94 from RMB 150,571,404.83, representing a rise of approximately 29.3%[13] - Inventory decreased to RMB 132,175,351.53 from RMB 167,708,747.71, showing a decline of about 21.1%[14] - The company's total liabilities as of the end of the third quarter of 2023 amounted to ¥198,443,093.98, compared to ¥126,993,106.00 at the end of the same period in 2022[18] - The company's total liabilities were not explicitly stated, but current liabilities included short-term borrowings of RMB 50,000,000.00 and accounts payable of RMB 59,838,563.43[14] - Total equity attributable to shareholders reached ¥1,456,121,394.80, an increase from ¥1,344,960,315.03 in the previous year[18] Shareholder Information - The company reported a total of 6,963 common shareholders at the end of the reporting period[8] - The top shareholder, Dou Baode, holds 117,649,000 shares, accounting for 47.34% of the total shares[8] - The company has a significant shareholder structure, with the top ten shareholders holding a total of 99.85% of the equity in the Qingdao Enfu Kai Jin Investment Fund Partnership[11] Research and Development - Research and development expenses for the first three quarters of 2023 were ¥24,621,458.89, up from ¥20,248,204.34 in the same period of 2022, indicating a focus on innovation[18] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[18] - The company experienced a significant increase in revenue due to growing demand from domestic and international customers during the reporting period[6] - The company has not disclosed any new product developments or market expansion strategies in the current report[12]

证券代码：605016 证券简称：百龙创园 公告编号：2023-040 山东百龙创园生物科技股份有限公司 关于 2023 年三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》之 《第十四号——食品制造》相关规定，现将山东百龙创园生物科技股份有限公司 （简称"公司"）2023 年三季度主要经营数据（未经审计）公告如下： 一、报告期主要经营数据 2023 年 1-9 月，实现营业收入 65,379.21 万元，同比增长 18.79%。实现主 营业务收入为 64,536.91 万元，同比增长 17.26%。实现归属于上市公司股东净 利润 14,133.95 万元，同比增长 19.79%。主营业务收入构成情况具体如下： 1、按产品分类情况 2、按地区分类情况 单位：万元 | | | 1 单位：万元 项目 2023 年 1-9 月 2022 年 1-9 月 金额 比例（%） 金额 比例（%） 益生元系列 18,127.05 28.09 19 ...

证券代码：605016 证券简称：百龙创园 公告编号：2023-039 山东百龙创园生物科技股份有限公司 关于投资建设泰国生产基地的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●投资标的名称：新建功能糖（阿洛酮糖生产线同时具备生产阿洛酮糖、结晶果 糖、异麦芽酮糖等结晶糖产品；抗性糊精生产线可联产低聚果糖、低聚异麦芽糖、低 聚半乳糖等益生元产品）生产基地项目。 ●投资金额：本项目预计总投资金额约 4.52 亿元人民币，其中公司投资金额约 1.32 亿元人民币，泰国子公司银行借款金额 3.2 亿元人民币（实际投资和银行借款金 额以中国及泰国当地相关主管部门批准的金额为准）。 ●相关风险提示： 本次对外投资事项属于董事会决策范围，无需提交股东大会审议。 （三）本次对外投资不构成关联交易，亦不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。 二、对外投资的基本情况 1、截至本公告披露之日，本次对外投资暂未取得国内境外投资备案或审批手续， 暂未取得泰国当地投资许可和企业登记等审批程序，尽管目前评 ...

二、监事会会议审议情况 证券代码：605016 证券简称：百龙创园 公告编号：2023-042 山东百龙创园生物科技股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 山东百龙创园生物科技股份有限公司（以下简称"公司"）第三届监事会第六 次会议于 2023 年 10 月 20 日上午 10：00 在公司办公楼一楼第二会议室召开，本 次会议的会议通知和材料已于 2023 年 10 月 10 日通过邮件等方式发出。会议由 监事会主席干昭波先生主持，应到监事 5 人，实到监事 5 人。 本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定，表决形成的决议合法、有效。 1 1、审议通过《关于 2023 年三季度报告的议案》 经审议，监事会认为： （1）公司 2023 年三季度报告的编制和审议程序符合法律、法规、《公司章 程》和公司内部管理制度等各项规定； （2）公司 2023 年三季度报告的内容和格式符合中国证监会和上海证券交易 ...

会议召开方式：上证路演中心网络互动 投资者可于 2023 年 10 月 20 日(星期五) 至 10 月 26 日(星期四)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 blcyzqb@sdblcy.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 山东百龙创园生物科技股份有限公司（以下简称"公司"）已于 2023 年 10 月 21 日发布公司 2023 年三季度报告，为便于广大投资者更全面深入地了解公司 2023 年三季度经营成果、财务状况，公司计划于 2023 年 10 月 27 日上午 09:00- 10:00 举行 2023 年三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 证券代码：605016 证券简称：百龙创园 公告编号：2023-043 山东百龙创园生物科技股份有限公司 关于召开 2023 年三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 10 月 27 日(星期五) ...

证券代码：605016 证券简称：百龙创园 公告编号：2023-041 山东百龙创园生物科技股份有限公司 第三届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 山东百龙创园生物科技股份有限公司（以下简称"公司"）第三届董事会第六 次会议于 2023 年 10 月 20 日上午 9：00 在公司办公楼一楼第二会议室召开，本 次会议的会议通知和材料已于 2023 年 10 月 10 日通过邮件等方式发出。会议由 董事长窦宝德先生主持，应到董事 9 人，实到董事 9 人，公司监事及董事会秘书 列席本次会议。 本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定，表决形成的决议合法、有效。 二、 董事会会议审议情况 1、审议通过《关于 2023 年三季度报告的议案》 具体内容详见公司同日在上海证券交易所官方网站及指定媒体上披露的 《2023 年三季度报告》。 审议结果：表决票 9 票，赞成票 9 票，反对票 0 票，弃权票 0 票。 2、审议通过 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[21]. - Basic earnings per share decreased by 40.32% to CNY 0.37 compared to the same period last year[22]. - Net profit attributable to shareholders increased by 16.12% to CNY 91,099,626.23, while net profit after deducting non-recurring gains and losses rose by 14.61% to CNY 84,946,555.49[25]. - Total revenue for the period was CNY 412,756,783.56, representing a growth of 5.15% year-on-year[25]. - The company's net assets attributable to shareholders increased by 4.53% to CNY 1,405,881,541.26[25]. - The total assets grew by 8.57% to CNY 1,598,119,882.87 compared to the end of the previous year[25]. - The company achieved total operating revenue of 412.76 million yuan in the first half of 2023, representing a year-on-year growth of 5.15%[62]. - Main business revenue reached 406.72 million yuan, with a year-on-year increase of 7.70%[62]. - The company reported a total of 117,649,000 shares under lock-up conditions, which will become tradable on April 21, 2024, after a 36-month lock-up period[174]. Market Expansion and Product Development - The company plans to launch two new product lines in Q3 2023, focusing on functional sugars and dietary fibers, aiming to capture a larger market share[21]. - Future outlook includes a revenue target of RMB 1 billion for the full year 2023, which would represent a 20% increase compared to 2022[21]. - The company is expanding its market presence in Southeast Asia, with plans to establish distribution partnerships in three new countries by the end of 2023[21]. - The company focuses on the development of prebiotics, dietary fibers, and health sweeteners, which are key growth areas for future business expansion[29]. - The company is advancing construction of a 30,000-ton soluble dietary fiber project and a 15,000-ton crystalline sugar project, expected to be operational by December 2023[66]. - The company has established a wholly-owned subsidiary in Qingdao to enhance international market expansion and attract high-end R&D talent[67]. Research and Development - Research and development expenses increased by 30% to RMB 50 million, reflecting the company's commitment to innovation and product development[21]. - As of the end of the reporting period, the company has been granted 64 invention patents and 1 utility model patent, covering core production technologies of its main products[46]. - The company has established partnerships with several universities and research institutions to enhance its R&D capabilities[52]. - The company obtained 6 authorized invention patents in the first half of 2023, including 5 domestic and 1 foreign patent, enhancing its innovation capabilities[72]. Financial Management - The company maintains a strong cash position with cash reserves of RMB 200 million, providing flexibility for future investments[21]. - Operating cash flow increased significantly by 66.79% to CNY 103,100,070.75 due to increased receivables and reduced procurement payments[23]. - The company reported a decrease in financial expenses by 82.93%, from -2,168,125.46 yuan to -370,143.20 yuan, indicating improved financial management[78]. - Cash and cash equivalents increased to ¥256.30 million, up 33.71% from ¥191.69 million, primarily due to net cash flow from operating activities[79]. Competitive Landscape - The global prebiotic industry includes major players such as Tate & Lyle and FrieslandCampina, while the dietary fiber industry features companies like Roquette and ADM, indicating a competitive landscape[34]. - The company is one of the few in the industry capable of large-scale production of over 70 different specifications of functional food ingredients, making it a leading manufacturer globally[34]. - The company is one of the largest producers of prebiotics, dietary fibers, and allulose in China, recognized as a top 100 enterprise in the light industry for several consecutive years[45]. Environmental and Sustainability Initiatives - The company has been recognized for its safety and environmental management, receiving awards for its commitment to workplace safety and environmental protection[106]. - The company has been recognized as a green factory by Shandong Province and the national government, highlighting its commitment to sustainable practices[108]. - The company is focused on developing a circular economy model, emphasizing resource efficiency and waste recycling[107]. - The company is committed to independent innovation and has implemented heat recovery projects to reduce wastewater and steam consumption[107]. Risks and Challenges - The management highlighted potential risks, including regulatory changes and market competition, which could impact future performance[21]. - The company faces risks related to market competition and product substitution, particularly if it fails to increase R&D investment and keep pace with technological advancements[90]. - The main raw materials for the company's products include starch and sugar, which are subject to significant price fluctuations due to climate and policy changes, potentially impacting profit margins[91]. - The company exports products primarily in USD, exposing it to exchange rate risks as its export volume increases[92].

山东百龙创园生物科技股份有限公司 第三届董事会第五次会议独立董事 出席会议的独立董事签名: 郑 江 let 護 2023 年 8 月 24 日 1、关于 2023 年半年度募集资金存放与使用情况专项报告的议案的独立意 见 经审议,公司募集资金存放与使用符合《上市公司监管指引第2号 -- 上市 公司募集资金管理和使用的监管要求(2022年修订)》和《上海证券交易所上市 公司自律监管指引第 1 号 -- 规范运作(2023年8月修订)》等相关法律法规和 内部管理制度的规定,没有与募集资金投资项目的实施计划相抵触,募集资金投 资项目正常有序实施,不存在损害股东特别是中小股东利益的情形。 (以下无正文) 郑万青 (本页无正文,为《山东百龙创园生物科技股份有限公司第三届董事会第五次会 议独立董事关于相关事项的独立意见》签字页 ) 关于相关事项的独立意见 根据《上市公司独立董事规则》《上市公司治理准则》《上海证券交易所上市 公司自律监管指引第 1 号-规范运作(2023年8月修订)》及《公司章程》等相 关规定,我们作为山东百龙创园生物科技股份有限公司(以下简称"公司")的 独立董事,基于独立客观的立场,本着审慎负责的态度 ...